RPGLIFENSE2 May 2023

RPG Life Sciences Limited has informed the Exchange about Investor Presentation

RPG Life Sciences Limited

RPO LIFE SCIENCES

May 02, 2023

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax:+91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Sandra - Kurla Complex, Sandra (East) Mumbai -400 051.

BSE Limited Corporate Relationship Department 25, P.J. Towers, Dalal Street, Mumbai 400 001.

Symbol: RPGLIFE

Scrip Code : 532983

Dear Sirs,

Sub: Investor Presentation.

In continuation of our Letter dated April 25, 2023, please find enclosed herewith Investor

Presentation for the quarter and year ended March 31, 2023, for the Results Earnings call

scheduled on Tuesday, May 2, 2023, at 3.30 p.m. 1ST.

Kindly take the same on record and disseminate appropriately.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited Digitally signed by RAJESH RAJESH RAMESH RAMESHSHIRAMBEKAR SHIRAMBEKAR

Date:2023.05.0213:08:26 +05'30' Rajesh Shirambekar Head - Legal & Company Secretary

An <>» RPG Company

RPG LIFE SCIENCES

An ~>>R,::.c:; Company

Investors’ Presentation FY23

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

An <l>» RPCi Company

R?G LIFE SCIENCES

RPG Group: One of India's fastest-growing diversified conglomerates

UN -EA,SHTALENT TOUCH LIVES 1QIUTPERF 10RM AND,@

RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses in Infrastructure, Technology, Tyres, Life Sciences, and plantation industries. Formerly known as Searle India, RPG Life Sciences was started as a joint venture with G.D Searle in 1968 and was rechristened to RPG Life Sciences in 1999 with G.D Searle withdrawing its India operations.

100+ years old Business Group |

$4 BN+ Revenue |

20000+ Employees |

BSE Listed Companies

One of India’s leading tyre Manufacturers

EPC major in infrastructure segments like T&D, Civil, Railways, Oil & Gas

__,,,,,, ZenSar Global Technology Consulting and IT services company

R?G LIFE SCIENCES

An Integrated Pharmaceutical company operating in Formulations and Synthetic APIs

Raychem ·RPG

Technology Solutions company catering to energy and infrastructure

An <l>» RPCi Company - - - - - - - - - - - - - - - - - - -

HARR/SONS MALAYALAM LIMITED

One of India’s largest plantation companies producing tea, rubber etc

R?G LIFE SCIENCES

RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.

Leader in Immunosuppressants

Domestic Formulations (DF)

Develop, manufacture and market branded formulations in India & Nepal

APIs 15%

International Formulations (IF) 18%

Domestic Formulations (DF) 67%

International Formulations (IF)

Develop, manufacture and sell oral solid dosage formulations in the generics and branded generics space across regulated and emerging Markets

APIs

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category

An <l>» RPCi Company

9 Therapies represented by High Equity Brands

50+ Markets Presence

3 Manufacturing Facilities

1200+ Employees

R?G LIFE SCIENCES

RPG Life Sciences Product Portfolio: Strong ‘Textbook’ brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies

Domestic Formulations (DF)

Key Therapies

Nephrology

Rheumatology

Oncology

Pain Management

Gastroenterology

Neuropsychiatry

Cardiovascular

Diabetes

Urology

Legacy Portfolio

Immunosuppressants

Text Book Brands

Azoran· Azathioprine

Mycophenolate Mofetil

'Aroimune ME. Cyclosporine

lklmunotac Tacrolimus

Azoran· Azathioprine

Spironolactone • < Lomotil Diphenoxylate HCl 'Nap_rJ,_~yn· Naproxen Serenace Haloperidol

Disopyramide Phosphate

Key Products

Specialty l:!~t~tit_ Adlumab·

Trastuzumab

'·,;:. ,,.11..o.·~-1 --.-':., ,,_

Adalimumab Ivzumao Bevacizumab

• •b~mabl00"'9/-m,g

~•.

Rituximab

,,,.,aw

Tofacitinib lr(JHigh"

lronl1DNltotiiltlYillSml(l0Dmglmlj

__ .... , ... -D.-)

'i>enbrV· Denosumab

New Portfolio

Chronic 'NuGliptin Vildagliptin

Gli tiNexf ...... ,- Teneligliptin

Dapagliflozin

Azelinidipine

·solifirsf

~~1511 t .ag

Mi~;;;mart'"S ''"'!t~:=:.~!:-\ ~;~:,"") More Smarfm More EfflcientJ

Life Cycle Management (Existing Products)

"2othioprio,e75ffl!!Tob..U

Azoran7s

-Aldactone·[a

Spironol1do111! 50mg + Frun1niOI! 20m~

'Naprosyn'::: +

""""'""'S<~•.-.'""''~""n• .. ,,.;~,,.,

·ru~Jn~:~l~~

Lomofen®LB

l opa••-2"'1)&licbc:i,ciO!la01" • '00mli,,n 'f""H

International Formulations (IF)

Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope

APIs

Key Products APIs - Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole, Diphenoxylate

An <l>» RPCi Company

R?G LIFE SCIENCES

Financial Performance

An <l>» RPCi Company

R?G LIFE SCIENCES

FY23: A Milestone Year

An <l>» RPCi Company

First time ever

500 Cr+ Revenues

100 Cr+ EBITDA

100 Cr+ Cash in Hand

1000 Cr+ Market Cap

R?G LIFE SCIENCES

Journey of RPG Life Sciences

Process Excellence Product Portfolio, People, Business Processes

Fundamentals Fixation Sales Hygiene, People, Organization

Sustainable Profitable Growth Revenues, Volumes, Margins

An <l>» RPCi Company

Benchmark Performance Profitability, Leverage, Liquidity Ratios

Scale-up

R?G LIFE SCIENCES

The Journey So Far: Fundamentals Fixation to Benchmark Performance

Fundamentals Fixation*

Process Excellence*

Sustainable Profitable Growth*

Benchmark Performance (= or <1000 cr Sales Cos*)

Business Hygiene

Product Portfolio

↑ Revenues

Profitability Ratios

• Expiries : 4.3%(FY19)→ 1.5% (FY23)

• Returns : 5.2% (FY19)→ 0.7% (FY23)

S&M Practices

• Discounts/Customer list revamp

• Salesforce revamp

• Sales/Marketing Practices revamp

Leadership & People Processes

• Leadership Changes

• Attrition Control

• 3-year New Product Grid

• New Product Launch Excellence

•

Legacy Brands LCM Best Practices

People

• Org. structure Re-design

• CTC Benchmarking

• Happiness/R&R Initiatives

Processes

• Sales & Marketing

• Quality, Mfg, R&D

• Technology adoption,

innovation institutionalisation

• Revenue: 330.2 Cr (FY19) → 512.8 Cr (FY23)

• # 1 in EBITDA Margin

• YoY Above-Market Growth

• # 1 in PBT Margin

• # 1 in PAT Margin

↑ Profits

Leverage Ratios

• EBITDA: 34.4 Cr (FY19) →107.5 Cr (FY23);↑~3X

• PBT : 15.1 Cr (FY19)→ 91.7(FY23); ↑~6X

• PAT : 10.8 Cr (FY19)→ 67.6 (FY23); ↑~6X

• # 1 in Interest Coverage Ratio

• # 1 in Debt/ Equity Ratio

↑Margins

Liquidity Ratios

• EBITDA: 10.4% (FY19) →21.0% (FY23) ↑~2X

• # 1 in Cashflow/Sales

• PBT : 4.6%(FY19)→17.9% (FY23) ↑~4X

• PAT : 3.3% (FY19) →13.2% (FY23) ↑~4X

* Illustrative examples out of a comprehensive Framework

#Comparison basis available data of 9M FY23; Published stock exchange data An <l>» RPCi Company

R?G LIFE SCIENCES

The Journey Ahead: Benchmark Performance to Scale-up

7 Pillars Identified

State-of-art ↑ Capacity PLANTS

Targeted Niche- focus R&D PIPELINE

Institutionalized INNOVATION

TECHNOLOGY enablement

M&As

Lead Therapy ADJACENT Spaces

Talent Development /Acquisition

• Modern,

Cost-efficient; cGMP Compliant; EU/PICS/TGA etc approved

• Higher

Capacity ~2X

• Focused New Product Grid across 3 segments

• R&D

Organisation strengthening

• Institutionalizat

• Technology

• M&A

ion of Innovation – Idea platforms, Rewards, Reviews

Identification and adoption

• All Areas –

Front-end, Back- end Functions

• Innovation

project(s) by each Department

Framework with criteria defined - Target Therapies, Brands Margin

• Identify & explore Adjacencies in RPGLS Strength therapies

An <l>» RPCi Company

• Org structure review & role/skill-gaps identification

• Talent

Development

• Talent

Acquisition in role/Skill-gaps

R?G LIFE SCIENCES

Revenues, PBT, Cashflows: A Trajectory of Strong y-o-y Growth

↑ Revenues

↑ PBT

↑ Cashflows

↑ EPS

Rs. Crores

512.8

440.2

375.6

389.1

330.2

91.7

73.2

53.6

41.8

15.1

115.2

40.9

31.1

70.3

40.3

24.2

17.5

6.5

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

FY19

-14.5

FY20 -3.9

FY21

FY22

FY23

An <l>» RPCi Company

11 11

FY19 FY20 FY21 FY22 FY23

R?G LIFE SCIENCES

Margins: A Trajectory of y-o-y Expansion despite Market Challenges EBITDA Margin :10.4% (FY19) to 21.0% (FY23);PBT Margin: 4.6% (FY19) to 17.9% (FY23); PAT Margin: 3.3% (FY19) to 13.2% (FY23)

EBITDA% 21.0%

PBT% 17.9%

PAT%

13.2%

20.3%

16.6%

11.7%

18.2%

13.8%

10.3%

15.9%

11.1%

7.7%

9.8%

8.1%

6.2%

6.0%

0.9%

0.5%

0.2%

0.4% 0.4%

0.4%

11.1% 10.4%

8.7%

4.2%

9.3%

4.7%

5.9%

3.9%

4.6%

3.3%

An <l>» RPCi Company

R?G LIFE SCIENCES

Key Ratios (ROCE, ROE, D/E) : A Trajectory of y-o-y uptrend

ROCE%

ROE%

Debt/Equity Ratio

- - l

23.6% 24.3%

27.9% 29.1%

18.5% 20.1%

16.4%

22.0%

0.22

11.0%

6.7%

0.06

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

FY19

FY20

Company continues to remain Debt-free

An <l>» RPCi Company

0.01

FY21

0.00

FY22

FY23

R?G LIFE SCIENCES

Q4 FY23 : Yet Another Strong Quarter

Revenue from Operations

- - - t

EBITDA & EBITDA Margin

17.8

14.8

[ ]

14.2%

~ •

15.0%

Q4 FY23

103.8

118.5

Q4 FY22

Q4 FY23

Q4 FY22

PAT & PAT Margin

- - t

10.4

8.7%

7.5

7.2%

(All figures in Rs. Crores except EPS in Rs.)

PBT & PBT Margin

10.9

10.5%

13.8

11.7%

Q4 FY22

Q4 FY23

EPS

-t

4.5

6.3

Figures in circle are Margins An <l>» RPCi Company

Q4 FY22

Q4 FY23

Q4 FY22

Q4 FY23

R?G LIFE SCIENCES

Full Year FY23 : Yet Another Strong Year of Performance

Revenue from Operations

- - - t - - - t

EBITDA & EBITDA Margin

512.8

440.2

FY22

FY23

89.4

20.3%

FY22

107.5

21.0%

FY23

(All figures in Rs. Crores except EPS in Rs.)

PBT & PBT Margin

- - t

73.2

16.6%

FY22

91.7

17.9%

FY23

PAT & PAT Margin

- - t

67.6

13.2%

FY23

51.5

11.7%

FY22

Figures in circle are Margins An <l>» RPCi Company

EPS

-t

40.9

31.1

FY22

FY23

R?G LIFE SCIENCES

Business Segment-wise Performance: FY23

Domestic Formulations (DF)

International Formulations (IF)

API

• Domestic Formulations contributed 67% to total sales of FY23 • • • New products* contribution improving consistently (currently >20%) on account of new

20% sales growth majorly driven by legacy products Better than market growth

launches in Specialty & Chronic segments and line extensions of legacy products Salesforce productivity improved to >5.0 Lakhs versus 3.4 Lakhs in earlier years

•

International Formulations contributed 18% to total sales of FY23 Robust sales growth of 18%

• • • New Products/Customers/Markets contribution continues to improve (currently ~30%)

API contributed 15% to total sales of FY23

• • Modest growth of 2% •

Continuous thrust on new customer development

*Launched FY19 Onwards

An <l>» RPCi Company

337.1

280.9

FY22

FY23

92.2

o...O/o

77.9

FY22

FY23

78.3

79.8

FY22

FY23

R?G LIFE SCIENCES

RPG Life Sciences ICRA Rating Reaffirmed in FY23

Long term rating reaffirmed at A Short term rating reaffirmed at A1

Outlook on long term rating has been retained as Stable

The rating reaffirmation factors:

 Strong brands in the Indian Pharmaceutical Industry  Considerable improvement in the operating performance on the back of

Improvement in sales hygiene

• • Cost rationalisation measures adopted since FY20

 A robust capital structure and strong coverage indicators based on

• Decline in the company’s debt levels • Healthy cash flows • No major debt-funded capital expenditure (capex)

 Expansion of product portfolio and geographical presence augur well for growth prospects

An <l>» RPCi Company

R?G LIFE SCIENCES

Business Strategy

An <l>» RPCi Company

R?G LIFE SCIENCES

Domestic Formulations (DF)

• Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • • • Good Customer Coverage - Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists • New Product Launches in New Category – Biosimilars as well as Chronic and Specialty segments

Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace Leading player in Immunosuppressant category

Business Strategy

5 pillars of profitable Domestic business growth

Product portfolio rejuvenation by building Chronic & Specialty portfolio with new launches

Strategic brand assets building through life cycle management (new line extensions, customer segments, disease segments, etc.)

Customer coverage deepening in targeted therapies by expanding field force and deploying digital

Sales force effectiveness augmentation by competencies building and productivity enhancement initiatives

An <l>» RPCi Company

Profitability improvement by Opex control, efficient manufacturing operations, sales hygiene as well as profitable product mix

R?G LIFE SCIENCES

Diligent implementation of Business Strategy is yielding results

Product portfolio rejuvenation

Strategic brand assets building

Customer coverage deepening

Sales force effectiveness augmentation

Profitability improvement

Naprosyn+ becomes the first 50 Cr+ Brand Franchise

Expansion of Target Customer base by 20,000 since FY19

Thrust on Building Mega Brands with a well-crafted Life Cycle Management Strategy for identified Legacy Brands

Year-on-Year consistent customer expansion in Target Therapies/ Specialties

Leveraging Digital to increase customer touchpoints and company/brand recall

Augmentation of Product Basket catering to Target Therapies/Specialties

*New Product Contribution

28%

FY23

FY19

Rheumatology

Strengthening Presence in • • Oncology Augmented Product Basket in • • • Urology

Cardiology Diabetology

*Launches since FY19

An <l>» RPCi Company

Monthly Revenue per MR (INR Lakhs)

↓Sales Expiries (%)

5.5

5.0

4.2

4.3

3.4

FY19 FY20 FY21 FY22 FY23

Consistent Productivity increase led by • •

Skilling programs Productivity-linked Incentive Structure Consistent Promo support

•

2.9

111

2.4

2.1

1.5

FY19 FY20 FY21 FY22 FY23

Diligent Management of both OPEX and COGs

Product Re-engineering

R?G LIFE SCIENCES

International Formulations (IF) Business: Overview and Strategy

• Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa •

Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world

• High quality and process orientation making us a preferred partner •

Investments in plant upgradation and capacity expansion

Business Strategy

3 pillars of step-wise Global business build up

Build immunosuppressant portfolio

Focus on products with specific/ competitive advantage e.g. -

Products needing Special manufacturing conditions like low RH/Temp Complex generic products Low Competition products

- -

An <l>» RPCi Company

Expand footprints in emerging/select markets like Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan, Thailand, and South Africa

R?G LIFE SCIENCES

APIs Business: Business Strategy and Way Forward

• High value, low volume, niche APIs • Mature stable molecules •

Provides backward integration to International Formulations business

•

Footprints across geographies - LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, etc. Strong customer focus – long-lasting relationship with big pharma and leading generic firms.

Business Strategy

Business continuity

Market/Customer Expansion (Existing Products)

Pipeline of Niche Product/Portfolio : - -

Immuno-suppressants Limited Competition products Backward integration of IF/DF

An <l>» RPCi Company

State-of-Art, EU/TGA approved Plant with Enhanced Capacity

R?G LIFE SCIENCES

Infrastructure & Backend Capabilities

An <l>» RPCi Company

R?G LIFE SCIENCES

Manufacturing Facilities

Formulations Unit 1, Ankleshwar

Formulations Unit 2, Ankleshwar

API Unit, Navi Mumbai

F1 unit caters to the domestic and emerging markets

• • Multipurpose plant with dedicated product lines for oral dosage forms including tablets,

liquids and powder

• WHO, Kenya, Nigeria approved

F2 unit caters to the regulated markets

• • Dedicated product lines for oral dosage (capsules & tablets) • • WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan,

Equipped to handle low RH and low temperature conditions products

Nigeria approved

• MF1: Multipurpose unit catering to emerging markets including India • MF2: Dedicated immunosuppressant facility catering to regulated and emerging markets

including India

• MF3: Multipurpose unit catering to regulated and emerging markets including India • WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO

An <l>» RPCi Company

R?G LIFE SCIENCES

Strong Backend Capabilities

Quality

• All critical SOPs harmonized through CQA • Quarterly internal audit of all plants by CQA • All critical deviations, change controls and market

complaints investigation approved by CQA

Regulatory

• Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and emerging markets Expertise of eCTD submissions Integrated project management activities

• •

•

Formulations R&D In addition to Formulations Development of IR, have capabilities to develop modified release & complex generics

• Dossiers gap analysis and fulfilment Tech transfer/site transfer activities • • GLP compliant analytical lab for Development and

Validation of Analytical Methods

Digitalisation Focus Areas

• Quality Management systems : e-QMS, e-DMS, e-LMS. • Access to critical manufacturing equipment through IRIS

scanner

• All QC instruments attached with dedicated software

and server

• All stability chambers with software control •

Secondary packing Complies with EUFMD requirement for Track and Trace.

An <l>» RPCi Company

R?G LIFE SCIENCES

Operational Highlights

An <l>» RPCi Company

R?G LIFE SCIENCES

Top 10 Operational Highlights

Comprehensive Life Cycle Management Strategy for DF Legacy products yielding results

New Product portfolio across identified segments contributing healthy double-digit growth

Legacy Product Naprosyn becomes the first 50 Cr+ Brand of the Company

The New Product Denosumab Sales ~5 Cr in the very first year of Launch

New Therapy – Rheumatology becoming formidable

The New Rheumatology Franchise grows to contributing significantly to Specialty Sales

Multiple Initiatives expanding Prescriber & Patient base

Medico Marketing Pyramid | Digital Marketing Pyramid | Disease Education

Revenue/Cost optimization projects driving results

Digitalisation & Innovation Agenda impacting key areas

Revenue Enhancement: New Products, Customers and Markets| Cost Optimization: Strict Opex Control, Digitalization and AVD

“RPGServ” 3.0 grows to 9 versions; Technology upgrades| eQMS, eDMS, eLMS for product Quality

Factories, R&D, Regulatory modernising up to support Frontend

Key Products Inhouse transfer| Modernization of both plants under execution | New Products development - WIP

Increasing Industry Interface and Performance Recognition

4 Industry Awards| Increased Traction in Investor meets and Media Interaction| RPG Best Corporate Performance award

“Happiness” Initiatives driving Happy Performance focused Culture

Happiness Score increase from 83% (FY21)→ 84% (FY22) → 87% (FY23)| Ranked #2 amongst RPG group companies

Headwinds Management

G C ompany

Diligent Management of Input Costs Increase

R?G LIFE SCIENCES

Digitalization Initiatives to Transform Business

Game Changer Customer Connect Initiative

Employee Connect Initiatives

• . -

9:27 ;

I!! Ill Ill

Ms. FalakJ lndal

My Service Requests

Logout

~ Scientific ~Update

~ Scientific ~ Support

C8 VID·19 Care

C8 VID·19 One Source

~ Scientific ~ Update

~ Scientific ~ Support

P<TIENT , EDUCATION MATERIAL

mil CONTACT l:iil us

PATIENT EDUCATION MATERIAL

Anytime, Anywhere Doctor Support Initiative

Industry First Initiative

2 .0

Digital Platform for comprehensive Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc

a r,ca

HR Chatbot for quick resolution of queries related to HR process and company policies

A digital platform for Salesforce Grievance Redressal

Initiatives in Plant Operations

Range of Services

>80,000 Key Opinion Leaders

e-QMS: Digital platform to track all 6 quality parameters

e-DMS: Digital platform to manage all manufacturing/quality documents

e-LMS: Digital platform to track training sessions on CGMP

All above represent Illustrative list of the initiatives

An <l>» RPCi Company

e- Access: Retina scanning for machine access

R?G LIFE SCIENCES

Digitalization Initiatives to Transform Business

Digital Retina Scanner

Intelligent Chilling Plant Manager

IOT based AHU monitoring system

Power Management System

• Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures

• Access to only

qualified professionals, Batch Management, Recipe Management, Au dit logs

• Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics

• Operates Pumps

•

& Chillers according to Operating Hours to maintain equal run time

• Automatically change over Working pump to Standby if Pump fails during operation

Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets enabling at all times

R?G LIFE SCIENCES

An <l>» RPCi Company

People Initiatives to build Performance Culture with focus on Happiness

I Feel Valued

You Excel. We Applaud. Motivation continuum

I Live a Purposeful & Balanced Life

RPGLS Values Champions Living organizational values

An <l>» RPCi Company

I Love My Work

~ ~

RPGLS Heroes Outperformance recognition

High Happiness Quotient

I Feel Connected

RPGLS Happiness Forums Leadership Connect – Month & Quarter

I am Growing

We Skill. You Grow. Competency building continuum

• • 0

Akanksha Career development

I cherish our Culture

RPGLS Parivar Tyohar-Utsav Shrankhla Digital RPGLS family get- together

R?G LIFE SCIENCES

Initiatives for building a Performance Driven Culture: Glimpses

Skilling

Rewards & Recognition

Employee engagement: Parivar Tyohar Utsav

Employee Connect

An <l>» RPCi Company

Idea Generation

Awards & Recognitions

An <l>» RPCi Company

R?G LIFE SCIENCES

RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’

Jamnalal Bajaj Award for Fair Business Practices (2021-22)

An <l>» RPCi Company

R?G LIFE SCIENCES

RPG Life Sciences Bagged Top Awards from IDMA

Industry Recognition to RPG Life Sciences

Best Patent Award

Best Corporate Citizen Award

An <l>» RPCi Company

R?G LIFE SCIENCES

We are Committed to our Transformation Agenda to continue our upward growth trajectory

Revenue Growth

Profit Growth and Focus on Cashflows

Strong Governance

Building Domestic Formulations Business via the identified 5 Pillars

Building Global Business through New Products/Markets/Customers

Formulations and API plants Modernization and Capacity expansion

Continued diligent thrust on cost control measures both in Opex and COGS

All operations within the Framework of strong Corporate Governance

Product Re-engineering

R&D Pipeline in identified niche areas

Process Efficiencies

New Opportunities : M&A

An <l>» RPCi Company

R?G LIFE SCIENCES

T H A N K

Y O U

An <l>» RPCi Company

R?G LIFE SCIENCES

← All Transcripts RPGLIFE Stock Page →

RPG Life Sciences Limited has informed the Exchange about Investor Presentation

Market Movers